The AIM-listed pharmaceuticals company said in a statement that the patent grant represented another major milestone in its commercial strategy, with the VAL201 portfolio having received patents in the US, UK, Japan, and Australia previously.
READ: ValiRx shoots higher, innovation effective at inducing programmed cell death in a wide range of cancers
ValiRx added that VAL201 is currently in a Phase I/II clinical study assessing its safety and tolerability as well as its effect in the treatment of prostate cancer and other solid tumours, with no dose-limiting toxicity or therapeutically-related side effects having been observed.
The group also said VAL201 has met and exceeded predicted safety and tolerability criteria set for the trial, with subjects showing preliminary therapeutic efficacy and significant changes in their prostate-specific antigen levels related to treatment with VAL201.
ValiRx added that pre-clinical studies have also shown efficacy in prostate, breast and ovarian cancer models as well as addressing endometriosis or hormone-induced abnormal cell growth in women.
Dr Satu Vainikka, ValiRx chief executive, said: "I am very pleased that VAL201 has received its European Union patent grant, hot on the heels of our receipt of a US patent grant [on 20 March 2018].
She added: “This latest grant now means that ValiRx has substantive patent protection stretching across the globe and I believe it further bolsters the Company's opportunity of securing a partnering deal, particularly in the light of the expansion of the VAL201 trial to more speedily reach VAL201's full therapeutic potential and potential anti-cancer impact".